Tsai T-C, Chen S-L
Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Arch Virol. 2003 Aug;148(8):1445-53. doi: 10.1007/s00705-003-0111-z.
Human papillomavirus type 16 (HPV-16) E5 protein, along with the more publicized E6 and E7 proteins of this virus, has been found to be oncogenic. E5 is a highly hydrophobic membrane-bound protein of 83 amino acids associated with the Golgi apparatus, endoplasmic reticulum, and nuclear membrane in infected cells. E5 can activate epidermal growth factor receptor (EGFR) through binding to the 16 kD subunit of protein pump ATPase leading to a reduced downregulation of EGFR receptors. The activation of EGFR can initiate biochemical cascades that lead to overexpression of a variety of protooncogenes and stimulate rapid cell growth. Moreover, E5 can inhibit the expression of tumor suppressor gene p21((WafI/SdiI/CipI)) and impair the control of cell cycle checkpoint. E5 protein has been identified as a potential tumor vaccine target antigen.
16型人乳头瘤病毒(HPV-16)E5蛋白,与该病毒中更受关注的E6和E7蛋白一样,已被发现具有致癌性。E5是一种由83个氨基酸组成的高度疏水的膜结合蛋白,与受感染细胞中的高尔基体、内质网和核膜相关。E5可通过与蛋白泵ATPase的16kD亚基结合来激活表皮生长因子受体(EGFR),从而导致EGFR受体下调减少。EGFR的激活可引发生化级联反应,导致多种原癌基因过度表达,并刺激细胞快速生长。此外,E5可抑制肿瘤抑制基因p21((WafI/SdiI/CipI))的表达,并损害细胞周期检查点的控制。E5蛋白已被确定为一种潜在的肿瘤疫苗靶抗原。